Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you're developing extracellular vesicle-based therapies for regenerative medicine, this NIH program is purpose-built to fund your research and translation pathway.
Report stale or inaccurate summary
What this is
This NIH program focuses on extracellular vesicle (EV) therapeutics—a cutting-edge regenerative medicine approach using naturally occurring cell-derived vesicles as drug delivery vehicles or direct therapeutic agents. The initiative appears designed to advance EV-based treatments through research, development, and potentially early commercialization pathways. CFDA 93.350 typically indicates support for general biomedical research grants, suggesting this could support basic research through translational work. Applicants should have substantial expertise in cell biology, EV isolation/characterization, therapeutic development, or clinical translation.
Who can apply
Eligible applicants likely include universities, research institutions, small businesses (under SBIR/STTR programs), and established biotech/pharma companies. Specific organizational size caps and geographic requirements are not detailed in the provided information; consult the full FOA for confirmation. U.S. organizations and individual researchers affiliated with eligible institutions typically qualify.
Topics: extracellular vesicles · regenerative medicine · cell therapy · therapeutic development · EV therapeutics · biotech funding
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.